Overview of the Surge#
MiNK Therapeutics, a clinical-stage biopharmaceutical company, saw its stock price soar by 80% on Tuesday. This significant increase followed the announcement of a collaboration with C-Further, aimed at developing a specialized cancer treatment for children.
Details of the Collaboration#
The partnership will provide MiNK Therapeutics with approximately $1.1 million in funding that does not require giving up any ownership in the company. This funding will support the development of their PRAME-targeted iNKT cell therapy, which is designed to treat various pediatric cancers, including sarcomas and acute myeloid leukemia. Additionally, MiNK will receive a share of any future commercial revenues from this therapy.
What is iNKT Cell Therapy?#
The therapy being developed uses a type of immune cell known as invariant natural killer T (iNKT) cells. These cells are engineered to target PRAME, a protein found in many pediatric tumors. The iNKT platform is unique because it can be produced in advance from healthy donors, allowing it to be used without the need for matching the patient's tissue type or undergoing intensive pre-treatment.
Future Steps and Research#
MiNK Therapeutics will lead this initiative, while researchers at the University of Southampton will conduct studies to assess the therapy's effectiveness and safety in treating pediatric cancers. The collaboration is non-exclusive, meaning MiNK can pursue other partnerships and projects independently. Payments related to this agreement will depend on reaching specific scientific milestones throughout the development process.
About C-Further Consortium#
C-Further is an international consortium focused on improving cancer treatments for children, particularly those with limited options. It is supported by organizations like Cancer Research Horizons and Great Ormond Street Hospital Charity, emphasizing the need for innovative therapies in pediatric oncology.